Lisa M Shulman
Overview
Explore the profile of Lisa M Shulman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
3223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akcimen F, Paquette K, Wild Crea P, Saffie-Awad P, Achoru C, Taiwo F, et al.
medRxiv
. 2025 Jan;
PMID: 39867380
Elucidating the genetic contributions to Parkinson's disease (PD) etiology across diverse ancestries is a critical priority for the development of targeted therapies in a global context. We conducted the largest...
2.
Khalil R, Shulman L, Gruber-Baldini A, Shakya S, Hausdorff J, von Coelln R, et al.
Sensors (Basel)
. 2025 Jan;
24(24.
PMID: 39771832
Mobility tasks like the Timed Up and Go test (TUG), cognitive TUG (cogTUG), and walking with turns provide insights into the impact of Parkinson's disease (PD) on motor control, balance,...
3.
Chahine L, Louie N, Solle J, Akcimen F, Ameri A, Augenbraun S, et al.
BMC Neurol
. 2024 Oct;
24(1):403.
PMID: 39434044
Determining the genetic contributions to Parkinson's disease (PD) across diverse ancestries is a high priority as this work can guide therapeutic development in a global setting. The genetics of PD...
4.
Khalil R, Shulman L, Gruber-Baldini A, Shakya S, Fenderson R, Van Hoven M, et al.
Sensors (Basel)
. 2024 Aug;
24(15).
PMID: 39124030
Quantitative mobility analysis using wearable sensors, while promising as a diagnostic tool for Parkinson's disease (PD), is not commonly applied in clinical settings. Major obstacles include uncertainty regarding the best...
5.
Kim H, Shulman L, Shakya S, Gruber-Baldini A
Parkinsonism Relat Disord
. 2023 Oct;
116:105892.
PMID: 37837675
Objective: The purpose of this cross-sectional study was to compare the independent contributions of medical comorbidity, cognition, and age on patient-reported outcomes in Parkinson's disease (PD). Methods: 572 PD patients...
6.
Ghourchian S, Gruber-Baldini A, Shakya S, Reich S, von Coelln R, Savitt J, et al.
J Relig Health
. 2023 Apr;
62(6):4177-4191.
PMID: 37099054
Spirituality and religious beliefs are important for coping with medical conditions. The dopaminergic system is involved in reward behavior, and its dysfunction in Parkinson Disease (PD) raises questions about religiosity...
7.
Glovinsky D, Gruber-Baldini A, Himelhoch S, Anderson K, Shulman L
Cogn Behav Neurol
. 2022 Oct;
35(4):255-262.
PMID: 36201624
Background: Co-occurring somatoform symptoms complicate the diagnosis and treatment of Parkinson disease (PD). Objective: To learn more about the relationship between somatoform symptoms and PD by comparing demographic and clinical...
8.
Hill E, Robak L, Al-Ouran R, Deger J, Fong J, Vandeventer P, et al.
Neurol Genet
. 2022 Jun;
8(4):e200002.
PMID: 35747619
Background And Objectives: Genetic variants affect both Parkinson disease (PD) risk and manifestations. Although genetic information is of potential interest to patients and clinicians, genetic testing is rarely performed during...
9.
Keshtkarjahromi M, Abraham D, Gruber-Baldini A, Schrader K, Reich S, Savitt J, et al.
Parkinsons Dis
. 2022 May;
2022:5535826.
PMID: 35585902
Background: The American Academy of Neurology Parkinson Disease (PD) quality measures include an annual diagnostic review. Objective: To investigate the frequency and pattern of changes in diagnoses between PD and...
10.
Albarmawi H, Zhou S, Shulman L, Gandhi A, Johnson A, Myers D, et al.
J Manag Care Spec Pharm
. 2022 Mar;
28(4):405-414.
PMID: 35332791
The progressive nature of Parkinson disease (PD), together with a lack of curative treatments, contributes to its economic burden. To estimate the longitudinal incremental costs attributable to PD among Medicare...